Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00626028 · ClinicalTrials.gov registry record · Phase 3
Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing
A Phase 3 study, sponsored by Mallinckrodt.
- Completed
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT00626028 is a Phase 3 study that has completed, run by Mallinckrodt. The registered enrollment target is 136 participants.
The verdict
NCT00626028, a Phase 3 study, has completed, sponsored by Mallinckrodt.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
Interventions
- DRUG Oxygen
- DRUG Nitric Oxide for inhalation
- DRUG Nitric Oxide plus Oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00626028
The ClinicalTrials.gov registry entry for NCT00626028 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Oxygen is the first listed.
NCT00626028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00626028 about?
NCT00626028 is a clinical study titled "Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing". The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.
What is the current status of trial NCT00626028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2004-09. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00626028?
The interventions under investigation include: Oxygen (DRUG), Nitric Oxide for inhalation (DRUG), Nitric Oxide plus Oxygen (DRUG).
Who is sponsoring clinical trial NCT00626028?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.